1
|
Campagna J, Czyszczon K, Little J, Selby C, Wick L, Ferreira D, Oriel K. The physical and psychosocial impact of a school-based running programme for adolescents with disabilities. J Intellect Disabil Res 2024; 68:181-192. [PMID: 37984471 DOI: 10.1111/jir.13104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 09/28/2023] [Accepted: 10/11/2023] [Indexed: 11/22/2023]
Abstract
BACKGROUND Adolescents with disabilities have fewer opportunities to participate in community-based fitness programmes. The purpose of this study was to examine the impact of a school-based running programme at a local middle school in Lebanon, Pennsylvania, on fitness and quality of life (QoL) in children with physical and cognitive disabilities in a life-skills classroom. METHODS Nineteen adolescents with diagnosed disabilities including intellectual disability (ID), autism spectrum disorder and Down syndrome were recruited from three life-skills classrooms to participate in a school-based running programme. The programme was designed to be implemented two times/week for 6 weeks by classroom teachers/aides. Physical therapy faculty and students developed the programme and assisted with implementation. Each session lasted 30 min, consisting of a warm-up and cooldown, relay races, games and timed runs. Pre- and post-test measures included physiological cost index (PCI) and Paediatric Quality of Life Inventory™ (PedsQL™). Pre- and post-test data were compared using Wilcoxon signed rank tests. Each week participants also completed a training log to reflect on the activity for the day. RESULTS Participants demonstrated significant improvements in PCI (P = 0.028) and the PedsQL™ (P = 0.008) following the running programme. CONCLUSIONS Results of this study suggest that participation in a 6-week school-based running programme may improve fitness and QoL in adolescents with disabilities.
Collapse
Affiliation(s)
- J Campagna
- Student, Lebanon Valley College, Annville, PA, USA
| | - K Czyszczon
- Student, Lebanon Valley College, Annville, PA, USA
| | - J Little
- Student, Lebanon Valley College, Annville, PA, USA
| | - C Selby
- Student, Lebanon Valley College, Annville, PA, USA
| | - L Wick
- Student, Lebanon Valley College, Annville, PA, USA
| | - D Ferreira
- Department of Physical Education and Exercise Science, Lander University, Greenwood, SC, USA
| | - K Oriel
- Department of Physical Therapy, Lebanon Valley College, Annville, PA, USA
| |
Collapse
|
2
|
Bandelier Q, Bastide C, Charvet AL, Leclercq L, Gondran-Tellier B, Campagna J, Long-Depaquit T, Daniel L, Rossi D, Lechevallier E, Baboudjian M. Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience. Fr J Urol 2024; 34:102537. [PMID: 37783635 DOI: 10.1016/j.purol.2023.09.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 09/12/2023] [Accepted: 09/19/2023] [Indexed: 10/04/2023]
Abstract
PURPOSE To report the long-term oncological outcomes of active surveillance (AS) in selected patients with favorable intermediate-risk (IR) prostate cancer (PCa). METHODS A retrospective database review of two academic centers was conducted to identify favorable IR PCa patients initially managed by AS between 2014 and 2022. Favorable IR PCa was defined by the presence of one single element of IR disease (i.e., PSA 10-20ng/mL, Gleason Grade Group [GG] 2, or cT2b). All patients were diagnosed and followed up according to a contemporary scheme, including MRI and image-guided biopsies. The primary endpoint was metastasis-free survival. RESULTS A total of 57 patients met our inclusion criteria and the median follow-up was 56months. During follow-up, there were no cases of metastasis or death due to PCa, but 6 deaths due to competing causes. A total of 25 (44%) and 6 patients (11%) had definitive treatment and GG 3 reclassification during follow-up, respectively. In multivariable Cox hazard regression analysis, the risk of undergoing definitive treatment was significantly associated with PSA density>0.15 (HR: 4.82, 95% CI: 1.47 to 15; P=0.01) and PI-RADS 4-5 lesions on mpMRI (HR: 2.48, 95% CI: 1.06 to 5.19; P=0.006). Interestingly, tumor burden (P=0.3) and GG (P=0.7) on biopsy were not associated with definitive treatment. CONCLUSIONS AS is a safe and valuable strategy for well-selected patients with favorable IR prostate cancer, with excellent oncological outcomes after five years' follow-up. LEVEL OF EVIDENCE: 4
Collapse
Affiliation(s)
- Q Bandelier
- Department of Urology, La Conception Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - C Bastide
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - A-L Charvet
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - L Leclercq
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - B Gondran-Tellier
- Department of Urology, La Conception Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - J Campagna
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - T Long-Depaquit
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - L Daniel
- Department of Pathology, Timone Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - D Rossi
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - E Lechevallier
- Department of Urology, La Conception Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - M Baboudjian
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France.
| |
Collapse
|
3
|
Cohn W, Zhu C, Campagna J, Bilousova T, Spilman P, Teter B, Li F, Guo R, Elashoff D, Cole GM, Avidan A, Faull KF, Whitelegge J, Wong DTW, John V. Integrated Multiomics Analysis of Salivary Exosomes to Identify Biomarkers Associated with Changes in Mood States and Fatigue. Int J Mol Sci 2022; 23:5257. [PMID: 35563647 PMCID: PMC9105576 DOI: 10.3390/ijms23095257] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 04/27/2022] [Accepted: 04/29/2022] [Indexed: 02/07/2023] Open
Abstract
Fatigue and other deleterious mood alterations resulting from prolonged efforts such as a long work shift can lead to a decrease in vigilance and cognitive performance, increasing the likelihood of errors during the execution of attention-demanding activities such as piloting an aircraft or performing medical procedures. Thus, a method to rapidly and objectively assess the risk for such cognitive fatigue would be of value. The objective of the study was the identification in saliva-borne exosomes of molecular signals associated with changes in mood and fatigue that may increase the risk of reduced cognitive performance. Using integrated multiomics analysis of exosomes from the saliva of medical residents before and after a 12 h work shift, we observed changes in the abundances of several proteins and miRNAs that were associated with various mood states, and specifically fatigue, as determined by a Profile of Mood States questionnaire. The findings herein point to a promising protein biomarker, phosphoglycerate kinase 1 (PGK1), that was associated with fatigue and displayed changes in abundance in saliva, and we suggest a possible biological mechanism whereby the expression of the PGK1 gene is regulated by miR3185 in response to fatigue. Overall, these data suggest that multiomics analysis of salivary exosomes has merit for identifying novel biomarkers associated with changes in mood states and fatigue. The promising biomarker protein presents an opportunity for the development of a rapid saliva-based test for the assessment of these changes.
Collapse
Affiliation(s)
- Whitaker Cohn
- The Drug Discovery Lab, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (W.C.); (C.Z.); (J.C.); (T.B.); (P.S.); (B.T.)
| | - Chunni Zhu
- The Drug Discovery Lab, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (W.C.); (C.Z.); (J.C.); (T.B.); (P.S.); (B.T.)
| | - Jesus Campagna
- The Drug Discovery Lab, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (W.C.); (C.Z.); (J.C.); (T.B.); (P.S.); (B.T.)
| | - Tina Bilousova
- The Drug Discovery Lab, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (W.C.); (C.Z.); (J.C.); (T.B.); (P.S.); (B.T.)
| | - Patricia Spilman
- The Drug Discovery Lab, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (W.C.); (C.Z.); (J.C.); (T.B.); (P.S.); (B.T.)
| | - Bruce Teter
- The Drug Discovery Lab, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (W.C.); (C.Z.); (J.C.); (T.B.); (P.S.); (B.T.)
| | - Feng Li
- Center for Oral/Head & Neck Oncology Research, Laboratory of Salivary Diagnostics, School of Dentistry, 10833 Le Conte Avenue, University of California Los Angeles, Los Angeles, CA 90095, USA; (F.L.); (D.T.W.W.)
| | - Rong Guo
- Department of Medicine Statistics Core, David Geffen School of Medicine, 1100 Glendon Avenue, University of California Los Angeles, Los Angeles, CA 90095, USA; (R.G.); (D.E.)
| | - David Elashoff
- Department of Medicine Statistics Core, David Geffen School of Medicine, 1100 Glendon Avenue, University of California Los Angeles, Los Angeles, CA 90095, USA; (R.G.); (D.E.)
| | - Greg M. Cole
- Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (G.M.C.); (A.A.)
| | - Alon Avidan
- Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (G.M.C.); (A.A.)
| | - Kym Francis Faull
- Pasarow Mass Spectrometry Laboratory, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, 760 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (K.F.F.); (J.W.)
| | - Julian Whitelegge
- Pasarow Mass Spectrometry Laboratory, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, 760 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (K.F.F.); (J.W.)
| | - David T. W. Wong
- Center for Oral/Head & Neck Oncology Research, Laboratory of Salivary Diagnostics, School of Dentistry, 10833 Le Conte Avenue, University of California Los Angeles, Los Angeles, CA 90095, USA; (F.L.); (D.T.W.W.)
| | - Varghese John
- The Drug Discovery Lab, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA; (W.C.); (C.Z.); (J.C.); (T.B.); (P.S.); (B.T.)
| |
Collapse
|
4
|
Campagna J, Touzani R, Gravis G, Marino P, Walz J, Bendiane MK, Bouhnik AD, Pignot G. [Does the announcement of cancer at the time of Non Muscle-Invasive Bladder Cancer diagnosis affect quality of life and adherence of patients? Data from the French prospective cohort VICAN]. Prog Urol 2021; 32:47-52. [PMID: 34462169 DOI: 10.1016/j.purol.2021.08.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 07/19/2021] [Accepted: 08/07/2021] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The information provided at the time of diagnosis of Non Muscle-Invasive Bladder Cancer (NMIBC) is highly variable. Well-informed patient are more involved in shared decisions. The objective of our study was to assess the information perceived by the patient at the time of NMIBC diagnosis and its impact on quality of life. METHODS The VICAN french cohort involved a representative sample of 4174 cancer patients and 5 years survivors. Patients reported outcomes (PROs) were collected by phone and self-questionnaire. Among the 118 NMIBC patients, the term used to define the pathology at diagnosis was prospectively evaluated. The impact on quality of life (using SF-12, EORTC-QLQ-C30 and HAD scale) and on adherence to the care protocol (endoscopic monitoring) has been assessed. RESULTS Only 26.8% of patients reported hearing the word « Cancer » at the time of NMIBC diagnosis. Conversely, 73.2% of them reported others terms, including « Tumor » (22%), « Polyp » (24%), and « Carcinoma » (17.1%). There was no difference in terms of physical, mental quality of life and anxiety, regardless of the term used. Adherence to the follow-up endoscopic protocol was better in the group of patients hearing the word "Cancer". CONCLUSION Three quarters of patients treated for NMIBC did not integrate the concept of « Cancer » at the time of diagnosis. Quality of life and anxiety did not differ significantly depending on the term used at diagnosis. However, adherence to care protocol appears to be higher when using the word "Cancer". LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- J Campagna
- Institut Paoli-Calmettes, department of surgical oncology 2, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - R Touzani
- Institut Paoli-Calmettes, Aix Marseille Univ, Inserm, IRD, SESSTIM, sciences économiques and sociales de la santé and traitement de l'information médicale, Marseille, France
| | - G Gravis
- Institut Paoli-Calmettes, medical oncology department, Marseille, France
| | - P Marino
- Institut Paoli-Calmettes, Aix Marseille Univ, Inserm, IRD, SESSTIM, sciences économiques and sociales de la santé and traitement de l'information médicale, Marseille, France
| | - J Walz
- Institut Paoli-Calmettes, department of surgical oncology 2, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | | | - A-D Bouhnik
- Institut Paoli-Calmettes, Aix Marseille Univ, Inserm, IRD, SESSTIM, sciences économiques and sociales de la santé and traitement de l'information médicale, Marseille, France
| | - G Pignot
- Institut Paoli-Calmettes, department of surgical oncology 2, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France.
| |
Collapse
|
5
|
Zhu C, Bilousova T, Focht S, Jun M, Elias CJ, Melnik M, Chandra S, Campagna J, Cohn W, Hatami A, Spilman P, Gylys KH, John V. Correction to: Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model. Mol Brain 2021; 14:108. [PMID: 34238327 PMCID: PMC8265003 DOI: 10.1186/s13041-021-00816-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- Chunni Zhu
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Tina Bilousova
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA.,School of Nursing, University of California, Los Angeles, CA, 90095, USA
| | - Samantha Focht
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Michael Jun
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Chris Jean Elias
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Mikhail Melnik
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Sujyoti Chandra
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Jesus Campagna
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Whitaker Cohn
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Asa Hatami
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Patricia Spilman
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | | | - Varghese John
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA.
| |
Collapse
|
6
|
Zhu C, Bilousova T, Focht S, Jun M, Elias CJ, Melnik M, Chandra S, Campagna J, Cohn W, Hatami A, Spilman P, Gylys KH, John V. Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model. Mol Brain 2021; 14:70. [PMID: 33875010 PMCID: PMC8056538 DOI: 10.1186/s13041-021-00776-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Accepted: 03/30/2021] [Indexed: 12/11/2022] Open
Abstract
Aim We have previously reported that cambinol (DDL-112), a known inhibitor of neutral sphingomyelinase-2 (nSMase2), suppressed extracellular vesicle (EV)/exosome production in vitro in a cell model and reduced tau seed propagation. The enzyme nSMase2 is involved in the production of exosomes carrying proteopathic seeds and could contribute to cell-to-cell transmission of pathological protein aggregates implicated in neurodegenerative diseases such as Parkinson’s disease (PD). Here, we performed in vivo studies to determine if DDL-112 can reduce brain EV/exosome production and proteopathic alpha synuclein (αSyn) spread in a PD mouse model. Methods The acute effects of single-dose treatment with DDL-112 on interleukin-1β-induced extracellular vesicle (EV) release in brain tissue of Thy1-αSyn PD model mice and chronic effects of 5 week DDL-112 treatment on behavioral/motor function and proteinase K-resistant αSyn aggregates in the PD model were determined. Results/discussion In the acute study, pre-treatment with DDL-112 reduced EV/exosome biogenesis and in the chronic study, treatment with DDL-112 was associated with a reduction in αSyn aggregates in the substantia nigra and improvement in motor function. Inhibition of nSMase2 thus offers a new approach to therapeutic development for neurodegenerative diseases with the potential to reduce the spread of disease-specific proteopathic proteins. Supplementary Information The online version contains supplementary material available at 10.1186/s13041-021-00776-9.
Collapse
Affiliation(s)
- Chunni Zhu
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Tina Bilousova
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA.,School of Nursing, University of California, Los Angeles, CA, 90095, USA
| | - Samantha Focht
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Michael Jun
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Chris Jean Elias
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Mikhail Melnik
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Sujyoti Chandra
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Jesus Campagna
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Whitaker Cohn
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Asa Hatami
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | - Patricia Spilman
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA
| | | | - Varghese John
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA.
| |
Collapse
|
7
|
Liu J, Campagna J, John V, Damoiseaux R, Mokhonova E, Becerra D, Meng H, McNally EM, Pyle AD, Kramerova I, Spencer MJ. A Small-Molecule Approach to Restore a Slow-Oxidative Phenotype and Defective CaMKIIβ Signaling in Limb Girdle Muscular Dystrophy. Cell Rep Med 2020; 1:100122. [PMID: 33205074 PMCID: PMC7659555 DOI: 10.1016/j.xcrm.2020.100122] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Revised: 08/07/2020] [Accepted: 09/21/2020] [Indexed: 12/21/2022]
Abstract
Mutations in CAPN3 cause limb girdle muscular dystrophy R1 (LGMDR1, formerly LGMD2A) and lead to progressive and debilitating muscle wasting. Calpain 3 deficiency is associated with impaired CaMKIIβ signaling and blunted transcriptional programs that encode the slow-oxidative muscle phenotype. We conducted a high-throughput screen on a target of CaMKII (Myl2) to identify compounds to override this signaling defect; 4 were tested in vivo in the Capn3 knockout (C3KO) model of LGMDR1. The leading compound, AMBMP, showed good exposure and was able to reverse the LGMDR1 phenotype in vivo, including improved oxidative properties, increased slow fiber size, and enhanced exercise performance. AMBMP also activated CaMKIIβ signaling, but it did not alter other pathways known to be associated with muscle growth. Thus, AMBMP treatment activates CaMKII and metabolically reprograms skeletal muscle toward a slow muscle phenotype. These proof-of-concept studies lend support for an approach to the development of therapeutics for LGMDR1.
Collapse
MESH Headings
- Acyltransferases/genetics
- Acyltransferases/metabolism
- Animals
- Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics
- Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism
- Calpain/deficiency
- Calpain/genetics
- Cardiac Myosins/genetics
- Cardiac Myosins/metabolism
- Cell Line
- Creatine Kinase, Mitochondrial Form/genetics
- Creatine Kinase, Mitochondrial Form/metabolism
- Female
- Gene Expression Regulation
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle Proteins/deficiency
- Muscle Proteins/genetics
- Muscle, Skeletal/drug effects
- Muscle, Skeletal/metabolism
- Muscle, Skeletal/pathology
- Muscular Dystrophies, Limb-Girdle/drug therapy
- Muscular Dystrophies, Limb-Girdle/genetics
- Muscular Dystrophies, Limb-Girdle/metabolism
- Muscular Dystrophies, Limb-Girdle/pathology
- Myoblasts/drug effects
- Myoblasts/metabolism
- Myoblasts/pathology
- Myosin Light Chains/genetics
- Myosin Light Chains/metabolism
- Oxidative Stress
- Phenotype
- Physical Conditioning, Animal
- Protein Isoforms/genetics
- Protein Isoforms/metabolism
- Pyrimidines/pharmacology
- Signal Transduction
- Small Molecule Libraries/pharmacology
Collapse
Affiliation(s)
- Jian Liu
- Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
| | - Jesus Campagna
- Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
| | - Varghese John
- Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
| | - Robert Damoiseaux
- Department of Pharmacology, David Geffen School of Medicine and Molecular Screening Shared Resource, Crump Imaging Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Ekaterina Mokhonova
- Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
| | - Diana Becerra
- Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
| | - Huan Meng
- Department of Medicine, David Geffen School of Medicine and California Nanosystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Elizabeth M. McNally
- Center for Genetic Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
| | - April D. Pyle
- Department of Microbiology, Immunology and Medical Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
- Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA
| | - Irina Kramerova
- Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
| | - Melissa J. Spencer
- Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
- Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA
| |
Collapse
|
8
|
Shu C, Parfenova L, Mokhonova E, Collado JR, Damoiseaux R, Campagna J, John V, Crosbie RH. High-throughput screening identifies modulators of sarcospan that stabilize muscle cells and exhibit activity in the mouse model of Duchenne muscular dystrophy. Skelet Muscle 2020; 10:26. [PMID: 32948250 PMCID: PMC7499884 DOI: 10.1186/s13395-020-00244-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 09/01/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Duchenne muscular dystrophy (DMD) is a degenerative muscle disease caused by mutations in the dystrophin gene. Loss of dystrophin prevents the formation of a critical connection between the muscle cell membrane and the extracellular matrix. Overexpression of sarcospan (SSPN) in the mouse model of DMD restores the membrane connection and reduces disease severity, making SSPN a promising therapeutic target for pharmacological upregulation. METHODS Using a previously described cell-based promoter reporter assay of SSPN gene expression (hSSPN-EGFP), we conducted high-throughput screening on libraries of over 200,000 curated small molecules to identify SSPN modulators. The hits were validated in both hSSPN-EGFP and hSSPN-luciferase reporter cells. Hit selection was conducted on dystrophin-deficient mouse and human myotubes with assessments of (1) SSPN gene expression using quantitative PCR and (2) SSPN protein expression using immunoblotting and an ELISA. A membrane stability assay using osmotic shock was used to validate the functional effects of treatment followed by cell surface biotinylation to label cell surface proteins. Dystrophin-deficient mdx mice were treated with compound, and muscle was subjected to quantitative PCR to assess SSPN gene expression. RESULTS We identified and validated lead compounds that increased SSPN gene and protein expression in dystrophin-deficient mouse and human muscle cells. The lead compound OT-9 increased cell membrane localization of compensatory laminin-binding adhesion complexes and improved membrane stability in DMD myotubes. We demonstrated that the membrane stabilizing benefit is dependent on SSPN. Intramuscular injection of OT-9 in the mouse model of DMD increased SSPN gene expression. CONCLUSIONS This study identifies a pharmacological approach to treat DMD and sets the path for the development of SSPN-based therapies.
Collapse
Affiliation(s)
- Cynthia Shu
- Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, USA
- Department of Integrative Biology and Physiology, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA
- Center for Duchenne Muscular Dystrophy, University of California Los Angeles, Los Angeles, CA, USA
| | - Liubov Parfenova
- Department of Integrative Biology and Physiology, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA
| | - Ekaterina Mokhonova
- Department of Integrative Biology and Physiology, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA
- Center for Duchenne Muscular Dystrophy, University of California Los Angeles, Los Angeles, CA, USA
| | - Judd R Collado
- Department of Integrative Biology and Physiology, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA
| | - Robert Damoiseaux
- Department of Molecular and Medicinal Pharmacology, University of California Los Angeles, Los Angeles, CA, USA
- California NanoSystems Institute, University of California Los Angeles, Los Angeles, CA, USA
| | - Jesus Campagna
- Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA
- Drug Discovery Lab, University of California Los Angeles, Los Angeles, CA, USA
| | - Varghese John
- Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA
- Drug Discovery Lab, University of California Los Angeles, Los Angeles, CA, USA
| | - Rachelle H Crosbie
- Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, USA.
- Department of Integrative Biology and Physiology, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA.
- Center for Duchenne Muscular Dystrophy, University of California Los Angeles, Los Angeles, CA, USA.
- Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 610 Charles E. Young Drive East, Terasaki Life Sciences Building, Los Angeles, CA, 90095, USA.
| |
Collapse
|
9
|
Fakhfakh S, Pouliquen C, Campagna J, Loverde K, Treacy P, Maubon T, Rybikowski S, Cambon S, Nguyen L, Deguibert J, Laurent M, Aveno J, Bokor E, Demontis C, Forestier C, Bereni F, Galland J, Montoya C, Mejri I, Cea C, Faucher M, Mokart D, Pignot G, Walz J. Patient care pathway hypnosedation in endo urology: An innovative alternative to general anesthesia. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34225-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
10
|
Bilousova T, Simmons BJ, Knapp RR, Elias CJ, Campagna J, Melnik M, Chandra S, Focht S, Zhu C, Vadivel K, Jagodzinska B, Cohn W, Spilman P, Gylys KH, Garg NK, John V. Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease. ACS Chem Biol 2020; 15:1671-1684. [PMID: 32352753 DOI: 10.1021/acschembio.0c00311] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
We report the discovery of a novel class of compounds that function as dual inhibitors of the enzymes neutral sphingomyelinase-2 (nSMase2) and acetylcholinesterase (AChE). Inhibition of these enzymes provides a unique strategy to suppress the propagation of tau pathology in the treatment of Alzheimer's disease (AD). We describe the key SAR elements that affect relative nSMase2 and/or AChE inhibitor effects and potency, in addition to the identification of two analogs that suppress the release of tau-bearing exosomes in vitro and in vivo. Identification of these novel dual nSMase2/AChE inhibitors represents a new therapeutic approach to AD and has the potential to lead to the development of truly disease-modifying therapeutics.
Collapse
Affiliation(s)
- Tina Bilousova
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
- School of Nursing, University of California, Los Angeles, California 90095, United States
| | - Bryan J. Simmons
- Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States
| | - Rachel R. Knapp
- Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States
| | - Chris J. Elias
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Jesus Campagna
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Mikhail Melnik
- School of Nursing, University of California, Los Angeles, California 90095, United States
| | - Sujyoti Chandra
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Samantha Focht
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Chunni Zhu
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Kanagasabai Vadivel
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Barbara Jagodzinska
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Whitaker Cohn
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Patricia Spilman
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| | - Karen H. Gylys
- School of Nursing, University of California, Los Angeles, California 90095, United States
| | - Neil K. Garg
- Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States
| | - Varghese John
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, California 90095, United States
| |
Collapse
|
11
|
Pignot G, Tourret M, Fakhfakh S, Rybikowski S, Maubon T, Campagna J, Rekik S, Brun C, Blache J, Walz J. Récupération améliorée après chirurgie (RAAC) pour cystectomie : impact sur la durée de séjour et les complications péri- et postopératoires. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Pignot G, Walz J, Rybikowski S, Maubon T, Fakhfakh S, Campagna J, Rekik S, Doisy L, Dermeche S, Guerin M, Vicier C, Marquette T, Gravis G. La thermo-chimiothérapie par HIVEC® chez les patients réfractaires au BCG : données d’efficacité à 1 an. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Fakhfakh S, Pouliquen C, Rekik S, Campagna J, Walz J, Brun C, Tourret M, Faucher M, Mokart D, Picini M, Massacrier S, Boulant S, Cini E, Pignot G. Évaluation de la satisfaction des patients pris en charge dans le protocole de réhabilitation améliorée après chirurgie (RAAC) en urologie à l’aide d’un questionnaire validé « EVAN-G ». Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Duong ATH, Simmons BJ, Alam MP, Campagna J, Garg NK, John V. Synthesis of Fused Indolines by Interrupted Fischer Indolization in a Microfluidic Reactor. Tetrahedron Lett 2019; 60:322-326. [PMID: 30631216 DOI: 10.1016/j.tetlet.2018.12.045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This study describes our development of a microfluidic reaction scheme for the synthesis of fused indoline ring systems found in several bioactive compounds. We have utilized a continuous-flow microfluidic reactor for the reaction of hydrazines with latent aldehydes through the interrupted Fischer indolization reaction to form fused indoline and azaindoline products. We have identified optimal conditions and evaluated the scope of this microfluidic reaction using various hydrazine and latent aldehyde surrogates. This green chemistry approach can be of general utility to rapidly produce indoline scaffolds and intermediates in a continuous manner.
Collapse
Affiliation(s)
- Alexander Tuan-Huy Duong
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095, United States
| | - Bryan J Simmons
- Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, United States
| | - Mohammad Parvez Alam
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095, United States
| | - Jesus Campagna
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095, United States
| | - Neil K Garg
- Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, United States
| | - Varghese John
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095, United States.,Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, United States
| |
Collapse
|
15
|
Campagna J, Toledano H, Rossi D, Bastide C. HIFU de rattrapage pour récidive après radiothérapie prostatique : morbidité et résultats carcinologiques à propos d’une série monocentrique de 45 patients. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Spilman P, Campagna J, Jagodzinska B, Zhu C, Bai D, Hatami A, Bilousova T, Jun M, Alam MP, Elias CJ, Soler J, Bredesen DE, John V. O5‐06‐06: NORMALIZATION OF HIPPOCAMPAL SIRTUIN 1 LEVELS IN A MURINE APOLIPOPROTEIN E4‐5XFAD MODEL OF AD RESTORES COGNITIVE FUNCTION. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.3030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Patricia Spilman
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Jesus Campagna
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Barbara Jagodzinska
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Chunni Zhu
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Dongsheng Bai
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Asa Hatami
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Tina Bilousova
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Michael Jun
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Mohammad Parvez Alam
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Chris Jean Elias
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Josh Soler
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Dale E. Bredesen
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| | - Varghese John
- Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease ResearchUniversity of California Los AngelesLos AngelesCAUSA
| |
Collapse
|
17
|
Bilousova T, Elias C, Miyoshi E, Alam MP, Zhu C, Campagna J, Vadivel K, Jagodzinska B, Gylys KH, John V. Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2. Biochem Biophys Res Commun 2018; 499:751-757. [PMID: 29604274 DOI: 10.1016/j.bbrc.2018.03.209] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Accepted: 03/27/2018] [Indexed: 11/19/2022]
Abstract
Targeting of molecular pathways involved in the cell-to-cell propagation of pathological tau species is a novel approach for development of disease-modifying therapies that could block tau pathology and attenuate cognitive decline in patients with Alzheimer's disease and other tauopathies. We discovered cambinol through a screening effort and show that it is an inhibitor of cell-to-cell tau propagation. Our in vitro data demonstrate that cambinol inhibits neutral sphingomyelinase 2 (nSMase2) enzyme activity in dose response fashion, and suppresses extracellular vesicle (EV) production while reducing tau seed propagation. Our in vivo testing with cambinol shows that it can reduce the nSMase2 activity in the brain after oral administration. Our molecular docking and simulation analysis reveals that cambinol can target the DK-switch in the nSMase2 active site.
Collapse
Affiliation(s)
- Tina Bilousova
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA; Gylys Lab, School of Nursing, University of California, Los Angeles, CA, USA
| | - Chris Elias
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA
| | - Emily Miyoshi
- Gylys Lab, School of Nursing, University of California, Los Angeles, CA, USA
| | - Mohammad Parvez Alam
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA
| | - Chunni Zhu
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA
| | - Jesus Campagna
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA
| | - Kanagasabai Vadivel
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA
| | - Barbara Jagodzinska
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA
| | - Karen Hoppens Gylys
- Gylys Lab, School of Nursing, University of California, Los Angeles, CA, USA
| | - Varghese John
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA.
| |
Collapse
|
18
|
Poksay KS, Sheffler DJ, Spilman P, Campagna J, Jagodzinska B, Descamps O, Gorostiza O, Matalis A, Mullenix M, Bredesen DE, Cosford NDP, John V. Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production. Front Pharmacol 2017; 8:46. [PMID: 28261092 PMCID: PMC5309220 DOI: 10.3389/fphar.2017.00046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2016] [Accepted: 01/20/2017] [Indexed: 02/06/2023] Open
Abstract
Alzheimer's disease (AD) is characterized by neuronal and synaptic loss. One process that could contribute to this loss is the intracellular caspase cleavage of the amyloid precursor protein (APP) resulting in release of the toxic C-terminal 31-amino acid peptide APP-C31 along with the production of APPΔC31, full-length APP minus the C-terminal 31 amino acids. We previously found that a mutation in APP that prevents this caspase cleavage ameliorated synaptic loss and cognitive impairment in a murine AD model. Thus, inhibition of this cleavage is a reasonable target for new therapeutic development. In order to identify small molecules that inhibit the generation of APP-C31, we first used an APPΔC31 cleavage site-specific antibody to develop an AlphaLISA to screen several chemical compound libraries for the level of N-terminal fragment production. This antibody was also used to develop an ELISA for validation studies. In both high throughput screening (HTS) and validation testing, the ability of compounds to inhibit simvastatin- (HTS) or cerivastatin- (validation studies) induced caspase cleavage at the APP-D720 cleavage site was determined in Chinese hamster ovary (CHO) cells stably transfected with wildtype (wt) human APP (CHO-7W). Several compounds, as well as control pan-caspase inhibitor Q-VD-OPh, inhibited APPΔC31 production (measured fragment) and rescued cell death in a dose-dependent manner. The effective compounds fell into several classes including SERCA inhibitors, inhibitors of Wnt signaling, and calcium channel antagonists. Further studies are underway to evaluate the efficacy of lead compounds - identified here using cells and tissues expressing wt human APP - in mouse models of AD expressing mutated human APP, as well as to identify additional compounds and determine the mechanisms by which they exert their effects.
Collapse
Affiliation(s)
- Karen S Poksay
- Bredesen Lab, Buck Institute for Research on Aging, Novato CA, USA
| | - Douglas J Sheffler
- Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla CA, USA
| | - Patricia Spilman
- Bredesen Lab, Buck Institute for Research on Aging, NovatoCA, USA; Drug Discovery Lab, Department of Neurology, University of California, Los AngelesCA, USA
| | - Jesus Campagna
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles CA, USA
| | - Barbara Jagodzinska
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles CA, USA
| | - Olivier Descamps
- Bredesen Lab, Buck Institute for Research on Aging, Novato CA, USA
| | - Olivia Gorostiza
- Bredesen Lab, Buck Institute for Research on Aging, Novato CA, USA
| | - Alex Matalis
- Bredesen Lab, Buck Institute for Research on Aging, Novato CA, USA
| | | | - Dale E Bredesen
- Bredesen Lab, Buck Institute for Research on Aging, NovatoCA, USA; Drug Discovery Lab, Department of Neurology, University of California, Los AngelesCA, USA
| | - Nicholas D P Cosford
- Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla CA, USA
| | - Varghese John
- Drug Discovery Lab, Department of Neurology, University of California, Los Angeles CA, USA
| |
Collapse
|
19
|
Spilman PR, Corset V, Gorostiza O, Poksay KS, Galvan V, Zhang J, Rao R, Peters-Libeu C, Vincelette J, McGeehan A, Dvorak-Ewell M, Beyer J, Campagna J, Bankiewicz K, Mehlen P, John V, Bredesen DE. Netrin-1 Interrupts Amyloid-β Amplification, Increases sAβPPα in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis 2017; 52:223-42. [PMID: 27060954 DOI: 10.3233/jad-151046] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Recent studies have shown that inoculation of susceptible mice with amyloid-β (Aβ) peptides accelerates Aβ deposition in the brain, supporting the idea that Aβ may be self-amplifying; however, the exact mechanism is not understood. Here we provide evidence that Aβ may self-amplify, in part, by inhibiting α-secretase ADAM10 (a disintegrin and metalloprotease) cleavage of full-length Aβ precursor protein (FL AβPP) and therefore allow greater β-secretase processing, and that Aβ itself is a substrate for ADAM10. Exposure of primary neuronal cultures from PDAβPP mice to exogenous rat Aβ1- 40 resulted in increased de novo human Aβ1-42 production and exposure of cells to Aβ decreased production of ADAM10 cleavage product soluble AβPPα (sAβPPα). In a cell-free assay, Aβ decreased ADAM10 cleavage of the chimeric substrate MBP-AβPPC125 and Aβ itself was apparently cleaved by the enzyme. The axonal guidance and trophic factor netrin-1, however, reduced the Aβ1- 40-induced Aβ1-42 increase, increased sAβPPα, and reversed the Aβ-induced sAβPPα decrease in vitro. In vivo, induction of netrin-1 expression in PDAβPPSwe/Ind transgenic mice resulted in reductions in both Aβ1-42 and Aβ1- 40, and ICV delivery of netrin-1 to PDAβPPSwe/Ind mice increased sAβPPα, decreased Aβ, and improved working memory. Finally, to support further study of netrin-1's potential as a therapeutic for Alzheimer's disease, pilot gene therapy studies were performed and a netrin mimetic peptide synthesized and tested that, like netrin, can increase sAβPPα and decrease Aβ1-42in vitro. Taken together, these data provide mechanistic insights into Aβ self-amplification and the ability of netrin-1 to disrupt it.
Collapse
Affiliation(s)
- Patricia R Spilman
- Buck Institute for Research on Aging, Novato, CA, USA.,Drug Discovery Laboratory, Department of Neurology & Easton Center for AD Research, University of California, Los Angeles, CA, USA
| | - Veronique Corset
- Buck Institute for Research on Aging, Novato, CA, USA.,Apoptosis, Cancer and Development Laboratory, University of Lyon Cancer Center, Centre Léon Bérard, Lyon, France
| | | | | | | | - Junli Zhang
- Buck Institute for Research on Aging, Novato, CA, USA
| | - Rammohan Rao
- Buck Institute for Research on Aging, Novato, CA, USA
| | | | | | | | | | - Janine Beyer
- Laboratory for Translational Neuroscience Research, Department of Neurological Surgery, University of California, San Francisco, CA, USA
| | - Jesus Campagna
- Buck Institute for Research on Aging, Novato, CA, USA.,Drug Discovery Laboratory, Department of Neurology & Easton Center for AD Research, University of California, Los Angeles, CA, USA
| | - Krystof Bankiewicz
- Laboratory for Translational Neuroscience Research, Department of Neurological Surgery, University of California, San Francisco, CA, USA
| | - Patrick Mehlen
- Apoptosis, Cancer and Development Laboratory, University of Lyon Cancer Center, Centre Léon Bérard, Lyon, France
| | - Varghese John
- Buck Institute for Research on Aging, Novato, CA, USA.,Drug Discovery Laboratory, Department of Neurology & Easton Center for AD Research, University of California, Los Angeles, CA, USA
| | - Dale E Bredesen
- Buck Institute for Research on Aging, Novato, CA, USA.,Drug Discovery Laboratory, Department of Neurology & Easton Center for AD Research, University of California, Los Angeles, CA, USA
| |
Collapse
|
20
|
Peters-Libeu C, Campagna J, Mitsumori M, Poksay KS, Spilman P, Sabogal A, Bredesen DE, John V. sAβPPα is a Potent Endogenous Inhibitor of BACE1. J Alzheimers Dis 2016; 47:545-55. [PMID: 26401691 DOI: 10.3233/jad-150282] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Proteolytic cleavage of the amyloid-β protein precursor (AβPP) by the enzyme BACE1 (BACE) is the initial step in production of amyloid-β peptide (Aβ), and as such has been a major target of Alzheimer's disease (AD) drug discovery efforts. Overproduction of Aβ results in neuronal cell death and accumulation of amyloid plaques in AD and in traumatic brain injury, and is also associated with stroke due to cerebral amyloid angiopathy. Herein we report for the first time that sAβPPα, the product of the cleavage of AβPP by α-secretase, is a potent endogenous direct inhibitor of the BACE enzyme, and that its inhibition is likely by an allosteric mechanism. Furthermore, using small-angle X-ray scattering, we show that sAβPPβ, which is identical to sAβPPα except for a 16-amino acid truncation at the carboxy terminus, adopts a completely different structure than sAβPPα and does not inhibit BACE. Our data thus reveal a novel mechanistic role played by sAβPPα in regulating overproduction of Aβ and restoring neuronal homeostasis and neuroprotection. Identification of sAβPPα as a direct BACE inhibitor may lead to design of new therapeutics targeting pathologies associated with overproduction of Aβ.
Collapse
Affiliation(s)
| | - Jesus Campagna
- Drug Discovery Laboratory, Department of Neurology, UCLA, Los Angeles, CA, USA
| | | | | | - Patricia Spilman
- Drug Discovery Laboratory, Department of Neurology, UCLA, Los Angeles, CA, USA
| | - Alex Sabogal
- Buck Institute for Research on Aging, Novato, CA, USA
| | - Dale E Bredesen
- Buck Institute for Research on Aging, Novato, CA, USA.,Drug Discovery Laboratory, Department of Neurology, UCLA, Los Angeles, CA, USA.,Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, CA, USA
| | - Varghese John
- Buck Institute for Research on Aging, Novato, CA, USA.,Drug Discovery Laboratory, Department of Neurology, UCLA, Los Angeles, CA, USA.,Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, CA, USA
| |
Collapse
|
21
|
Alam MP, Jagodzinska B, Campagna J, Spilman P, John V. C-O bond Formation in a Microfluidic Reactor: High Yield S NAr Substitution of Heteroaryl Chlorides. Tetrahedron Lett 2016; 57:2059-2062. [PMID: 27152054 DOI: 10.1016/j.tetlet.2016.03.095] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
This study describes our development of a novel and efficient procedure for C-O bond formation under mild conditions, for coupling heteroaryl chlorides with phenols or primary aliphatic alcohols. We utilized a continuous-flow microfluidic reactor for C-O bond formation in electron-deficient pyrimidines and pyridines in a much more facile manner with a cleaner reaction profile, high yield, quick scalability and without the need for the transition metal catalyst. This approach can be of general utility to make C-O bond containing intermediates of industrial importance in a continuous and safe manner.
Collapse
Affiliation(s)
- Mohammad Parvez Alam
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095
| | - Barbara Jagodzinska
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095
| | - Jesus Campagna
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095
| | - Patricia Spilman
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095
| | - Varghese John
- Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095
| |
Collapse
|
22
|
Campagna J, Spilman P, Zhang Q, Poksay K, Bilousova T, Jagodzinska B, Descamps O, Gorostiza O, Matalis A, Bredesen DE, John V. P1‐089: Targeting trka inhibition in Alzheimer's disease therapy. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jesus Campagna
- University of CaliforniaLos AngelesCAUSA
- Easton Center for Alzheimer's Disease ResearchLos AngelesCAUSA
| | - Patricia Spilman
- University of CaliforniaLos AngelesCAUSA
- Easton Center for Alzheimer's Disease ResearchLos AngelesCAUSA
| | - Qiang Zhang
- Buck Institute for Research on AgingNovatoCAUSA
| | | | - Tina Bilousova
- University of CaliforniaLos AngelesCAUSA
- Easton Center for Alzheimer's Disease ResearchLos AngelesCAUSA
| | - Barbara Jagodzinska
- University of CaliforniaLos AngelesCAUSA
- Easton Center for Alzheimer's Disease ResearchLos AngelesCAUSA
| | | | | | | | - Dale E. Bredesen
- University of California, Los AngelesLos AngelesCAUSA
- Mary S. Easton Center for Alzheimer's Disease ResearchUCLALos AngelesCAUSA
| | - Varghese John
- University of California, Los AngelesLos AngelesCAUSA
- Mary S. Easton Center for Alzheimer's Disease ResearchUCLALos AngelesCAUSA
| |
Collapse
|
23
|
Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, Gorostiza O, Campagna J, Jagodzinska B, Bredesen DE, John V. AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease. J Alzheimers Dis 2014; 37:343-55. [PMID: 23948888 DOI: 10.3233/jad-130578] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
A systematic approach was used to identify AβPP-selective BACE inhibitors (ASBI) and to evaluate their in vivo ability to modulate AβPP processing selectively. We identified a bioflavonoid nutritional supplement as a molecular lead that acts as an ASBI in cell models, and show that increasing brain levels of this bioflavonoid through a pro-drug approach leads to reduction of Aβ42 in an Alzheimer's disease mouse model. ASBIs represent a novel class of candidate therapeutic agents for Alzheimer's disease.
Collapse
|
24
|
Spilman P, Descamps O, Gorostiza O, Peters-Libeu C, Poksay KS, Matalis A, Campagna J, Patent A, Rao R, John V, Bredesen DE. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. Brain Res 2013; 1551:25-44. [PMID: 24389031 DOI: 10.1016/j.brainres.2013.12.029] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Revised: 11/22/2013] [Accepted: 12/23/2013] [Indexed: 12/31/2022]
Abstract
Tropisetron was identified in a screen for candidates that increase the ratio of the trophic, neurite-extending peptide sAPPα to the anti-trophic, neurite-retractive peptide Aβ, thus reversing this imbalance in Alzheimer's disease (AD). We describe here a hierarchical screening approach to identify such drug candidates, moving from cell lines to primary mouse hippocampal neuronal cultures to in vivo studies. By screening a clinical compound library in the primary assay using CHO-7W cells stably transfected with human APPwt, we identified tropisetron as a candidate that consistently increased sAPPα. Secondary assay testing in neuronal cultures from J20 (PDAPP, huAPP(Swe/Ind)) mice showed that tropisetron consistently increased the sAPPα/Aβ 1-42 ratio. In in vivo studies in J20 mice, tropisetron improved the sAPPα/Aβ ratio along with spatial and working memory in mice, and was effective both during the symptomatic, pre-plaque phase (5-6 months) and in the late plaque phase (14 months). This ameliorative effect occurred at a dose of 0.5mg/kg/d (mkd), translating to a human-equivalent dose of 5mg/day, the current dose for treatment of postoperative nausea and vomiting (PONV). Although tropisetron is a 5-HT3 receptor antagonist and an α7nAChR partial agonist, we found that it also binds to the ectodomain of APP. Direct comparison of tropisetron to the current AD therapeutics memantine (Namenda) and donepezil (Aricept), using similar doses for each, revealed that tropisetron induced greater improvements in memory and the sAPPα/Aβ1-42 ratio. The improvements observed with tropisetron in the J20 AD mouse model, and its known safety profile, suggest that it may be suitable for transition to human trials as a candidate therapeutic for mild cognitive impairment (MCI) and AD, and therefore it has been approved for testing in clinical trials beginning in 2014.
Collapse
Affiliation(s)
- Patricia Spilman
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Olivier Descamps
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Olivia Gorostiza
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Clare Peters-Libeu
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Karen S Poksay
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Alexander Matalis
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Jesus Campagna
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Alexander Patent
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Rammohan Rao
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA
| | - Varghese John
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA; Dominican University of California, San Rafael, CA 94901, USA
| | - Dale E Bredesen
- Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA; Department of Neurology, University of California, San Francisco, CA 94143, USA.
| |
Collapse
|
25
|
Friberg TR, Campagna J. Central serous chorioretinopathy: an analysis of the clinical morphology using image-processing techniques. Graefes Arch Clin Exp Ophthalmol 1989; 227:201-5. [PMID: 2737478 DOI: 10.1007/bf02172748] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
We used a digital image processor to make multiple measurements from the fluorescein angiograms of 53 cases of central serous chorioretinopathy (CSC) associated with single leaks. We determined the area of the base of each serous detachment, the location of its geometric center (CM), the area of the RPE leak, the distance from the fovea to the leak, and the distance from the leak to the CM. The distribution of leaks across the base of the detachments was nonrandom (P less than 0.005) with leaks clustering near the centers of the detachments. When the leak was found within 1 disc diameter from the fovea, the center of the detachment was located virtually at the foveola, suggesting that the central macula is predisposed to the development of CSC. Detachments associated with "smokestack" leaks were significantly larger than those associated with round pinpoint leaks (P less than 0.02).
Collapse
Affiliation(s)
- T R Friberg
- Department of Ophthalmology, University of Pittsburgh, PA
| | | |
Collapse
|
26
|
Campagna J, Lavoie PE, Birnbaum NS, Furman DP. Lyme disease in northern California. West J Med 1983; 139:319-23. [PMID: 6636745 PMCID: PMC1021513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Lyme disease is a recently described clinical entity with cutaneous, neurologic, articular and cardiac manifestations. Since the original description of the disease in 1977, more than 500 cases have been reported. Although the vast majority of patients have been from the area near Lyme, Connecticut, we have seen four patients from northern California with various aspects of Lyme disease. This diagnosis should be considered in patients who have traveled to tick regions and who have a distinctive skin lesion (erythema chronicum migrans). Clinical and epidemiologic evidence suggests the disease is transmitted by a tick, lxodes dammini in the eastern United States, lxodes pacificus in the West and lxodes ricinus in Europe. The etiologic agent, a new spirochete, may have been recently discovered.
Collapse
|
27
|
Dafforn A, Anderson M, Ash D, Campagna J, Daniel E, Horwood R, Kerr P, Rych G, Zappitelli F. The mode of binding of potential transition-state analogs to acetylcholinesterase. Biochim Biophys Acta 1977; 484:375-85. [PMID: 20963 DOI: 10.1016/0005-2744(77)90093-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Phenylacetone, 4-phenyl-2-butanone, and 4-oxopentyltrimethylammonium chloride were tested as potential transition state analogs for eel acetylcholinesterase (acetylcholine hydrolase, EC 3.1.1.7). Phenylacetone is a competitive inhibitor of the enzyme but not a transition state analog, since its binding constant is similar to that for the substrate phenyl acetate. 4-Phenyl-2-butanone binds 6-18 times more tightly than the inhibitors 4-phenyl-2-butanol and N-benzylacetamide and the substrate benzyl acetate and also blocks inactivation of the enzyme with methanesulfonyl fluoride. However, its binding is independent of pH in the range 5-7.5, whereas both V and V/Km for benzyl acetate hydrolysis decrease with decreasing pH in this range. These data indicate a specific but weak interaction between the ketone carbonyl and the enzyme, but probably do not justify considering this compound a transition state analog. 4-oxopentyltrimethylammonium iodide has previously been shown to bind about 125 times more strongly than the substrate acetylcholamine. It also binds about 375 times more strongly than the alcohol 4-hydroxypentyltrimethylammonium iodide. Furthermore, the ketone protects the enzyme from inactivation by methansulfony fluoride, while the corresponding quaternary ammonium alcohol accelerates this inactivation reaction. This additional information confirms that the ketone is a transition state analog.
Collapse
|
28
|
Hill SD, Campagna J, Long D, Munch J, Naecker S. An exploratory study of the use of two response keyboards as a means of communication for the severly handicapped child. Percept Mot Skills 1968; 26:699-704. [PMID: 5657708 DOI: 10.2466/pms.1968.26.3.699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
A technique for developing communication skills for the severely handicapped child was devised. Two instruments are described along with preliminary findings regarding their use.
Collapse
|